FOXM1 and hydrops fetalis: Notably, intracoronary infusion via percutaneous catheter‐based approaches has gained appeal due to its limited invasiveness.[55, 56] Our translational study has demonstrated the feasibility, long‐term therapeutic effectiveness, and favorable safety profile of cardiac AAV9‐Foxm1 gene therapy in preclinical models of HF.